Research articles
A New Era in Duchenne Muscular Dystrophy: Disease-Modifying Therapies in Development
The Best-Selling Neurology Drugs in Q3 2025: Where Multibillion-Dollar Franchises Are Taking Shape
The Next Generation of Chronic Spontaneous Urticaria Treatments: Targets, Approvals, and Pipeline Momentum
Inside Big Pharma Portfolios Part 2: What Drove Revenue in Q3 2025
Johnson and Johnson Q3 2025 Earnings: Oncology and Immunology Drive Growth After Strategic Reset
Advancing Beyond Statins: Emerging Cholesterol-Lowering Medicines Reshaping Lipid Management
AbbVie Q3 2025 Earnings: Skyrizi and Rinvoq Drive Post-Humira Growth
